Stage IV Skin Melanoma
Information
- Disease name
- Stage IV Skin Melanoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03719131 | Active, not recruiting | Phase 2 | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | June 5, 2019 | September 13, 2024 |
| NCT00026221 | Completed | Phase 2 | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | November 2001 | November 2013 |
| NCT00110019 | Completed | Phase 3 | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | June 2005 | August 2012 |
| NCT00387751 | Completed | Phase 2 | Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | August 2006 | January 2010 |
| NCT00397982 | Completed | Phase 2 | Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma | January 2008 | July 2013 |
| NCT00866177 | Completed | Phase 2 | MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma | March 2009 | September 2013 |
| NCT01131234 | Completed | Phase 1 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | May 2010 | September 2014 |
| NCT01196416 | Completed | Phase 1/Phase 2 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma | August 2010 | August 2015 |
| NCT01460875 | Completed | N/A | Recombinant Interferon Alfa-2b in Treating Patients With Melanoma | April 22, 2008 | January 5, 2014 |
| NCT01522820 | Completed | Phase 1 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | March 2012 | July 2016 |
| NCT01961115 | Completed | Phase 2 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | September 13, 2013 | May 18, 2017 |
| NCT01989559 | Completed | Phase 1 | Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery | October 2002 | September 2013 |
| NCT02318771 | Completed | Phase 1 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | February 5, 2015 | March 25, 2021 |
| NCT02320305 | Completed | Early Phase 1 | MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery | January 27, 2015 | April 11, 2019 |
| NCT02716948 | Completed | Phase 1 | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | June 23, 2016 | August 27, 2021 |
| NCT02858869 | Completed | Phase 1 | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | October 4, 2016 | October 28, 2023 |
| NCT02941744 | Completed | Phase 1/Phase 2 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases | March 2016 | January 2019 |
| NCT03112668 | Completed | N/A | Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners | December 6, 2017 | January 25, 2018 |
| NCT03229278 | Completed | Phase 1 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | October 3, 2017 | October 30, 2022 |
| NCT01789827 | Completed | Early Phase 1 | Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy | March 2014 | June 27, 2018 |
| NCT01886235 | Completed | N/A | Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery | September 4, 2013 | May 6, 2020 |
| NCT01960634 | Completed | Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma | April 2013 | May 2015 | |
| NCT00019682 | Completed | Phase 3 | Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma | December 1999 | May 2011 |
| NCT01970527 | Terminated | Phase 2 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | March 2014 | June 21, 2019 |
| NCT02748564 | Terminated | Phase 2 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | March 21, 2017 | June 5, 2023 |
| NCT02650635 | Terminated | Phase 1 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | February 5, 2016 | June 1, 2017 |
| NCT01307618 | Terminated | Phase 2 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma | February 2011 | February 2015 |
| NCT01744171 | Terminated | Phase 1 | Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma | March 26, 2013 | June 11, 2018 |
| NCT03154190 | Unknown status | N/A | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | August 8, 2017 | August 30, 2022 |
| NCT02654821 | Unknown status | Phase 1/Phase 2 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma | March 2012 | January 2020 |
| NCT02812693 | Withdrawn | Phase 1/Phase 2 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | November 4, 2016 | November 20, 2017 |